- Tytuł:
- Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
- Autorzy:
- Źródło:
- In The Lancet Oncology January 2024 25(1):117-125
Czasopismo naukowe